Abstract: CRF antagonists of Formulas I-V, wherein the B group in the Formulas contains an oxime
The variables in the Formulas have the meanings described herein.
Abstract: This invention relates to compounds of formula (I), wherein A, B, D, E, K, G, Z, R3 and R5 are defined as in the specification, and to the pharmaceutically acceptable salts of such compounds. Compounds (I) are corticotropin releasing factor (hormone) CRF (CRH) antagonists.
Abstract: There is provided a compound of formula I,
wherein R1, R2, R3, X and Y have meanings given in the description, which are useful in the prophylaxis and in the treatment of pruritus.
Type:
Grant
Filed:
May 23, 2000
Date of Patent:
November 12, 2002
Assignee:
Pfizer Inc
Inventors:
Stephen Paul Gibson, Ivan Tommasini, Brian Scott Bronk
Abstract: There is provided a compound of formula I,
wherein Het1, T, X, R1, R2 and R3 have meanings given in the description, which are useful in the prophylaxis and in the treatment of diseases mediated by opiate receptors, such as pruritus.
Type:
Grant
Filed:
May 18, 2000
Date of Patent:
August 27, 2002
Assignee:
Pfizer Inc
Inventors:
Stephen Paul Gibson, Ivan Tommasini, Kimberley Verrier, Lee Roberts, Brian Scott Bronk, Richard Edward Armer
Abstract: The present invention relates to compounds of formula I,
and to their pharmaceutically acceptable salts. Compounds of formula I exhibit activity as serotonin, norepinephrine, and dopamine reuptake inhibitors and can be used in the treatment of central nervous system and other disorders.
Abstract: The present invention relates to novel atropisomers of 2,3-disubstituted-(5,6)-heteroarylfused-pyrimidin-4-ones, pharmaceutical compositions containing such compounds the use of such compounds to treat neurodegenerative, psychotropic, and drug and alcohol induced central and peripheral nervous system disorders.
Type:
Grant
Filed:
July 23, 1998
Date of Patent:
November 27, 2001
Assignee:
Pfizer Inc
Inventors:
Bertrand L. Chenard, Willard M. Welch, Jr.
Abstract: The present invention relates to novel 2,3 disubstituted-4(3H)-quinazolinone compounds of the formula I:
wherein, R1, R2 and R3 are as defined in the specification; and to the pharmaceutically acceptable salts of compounds of formula I, and to pharmaceutical compositions and methods of treating neurodegenerative and CNS-trauma related conditions.
Type:
Grant
Filed:
November 23, 1999
Date of Patent:
October 16, 2001
Assignee:
Pfizer Inc
Inventors:
Mark L. Elliott, Willard M. Welch, Bertrand L. Chenard
Abstract: The invention is directed to the mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one, pharmaceutical compositions containing said ziprasidone mesylate dihydrates, and methods of adminsitering the ziprasidone mesylate dihydrates to treat psychotic diseases.
Type:
Grant
Filed:
August 30, 1999
Date of Patent:
June 12, 2001
Assignee:
Pfizer Inc
Inventors:
Frank R. Busch, Carol A. Rose, Russell J. Shine
Abstract: The present invention relates to 6-phenyl-pyridin-2-ylamine derivatives of the formula
wherein G, R1 and R2 are defined as in the specification, that exhibit activity as nitric oxide synthase (NOS) inhibitors, to pharmaceutical compositions containing them, and to their use in the treatment and prevention of central nervous system and other disorders.
Abstract: Substituted pyrido[1,2-a]pyrazines of general formula I; wherein Ar and Ar1 represent various carbocyclic and heterocyclic aromatic rings; A represents O, S, SO, SO2, CHOH, C═O, or —(CR3R4); and n is 0-2, as well as precursors thereto, are ligands for dopamine receptor subtypes and serotonin (5HT) within the body and are therefore useful in the treatment of disorders of the dopamine and serotonin systems:
Type:
Grant
Filed:
August 5, 1999
Date of Patent:
May 15, 2001
Assignee:
Pfizer Inc
Inventors:
Kishor A. Desai, Anton F. J. Fliri, Mark A. Sanner
Abstract: The invention relates to a method of treating dyskinesias associated with dopamine agonist therapy in a mammal which comprises administering to said mammal a compound, as defined herein, which is an antagonist of the AMPA receptor. Dopamine agonist therapy, as referred to in the present invention, is generally used in the treatment of a central nervous system disorder such as Parkinson's disease.
Type:
Grant
Filed:
September 4, 1998
Date of Patent:
October 24, 2000
Assignee:
Pfizer Inc
Inventors:
Bertrand L. Chenard, Willard M. Welch, Frank S. Menniti
Abstract: Mesylate Trihydrate Salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydr o-2(1H)-indol-2-one (=Ziprasidone), Its Preparation and Its Use as Dopamine D2 AntagonistThe invention relates to the mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydr o-2(1H)-indol-2-one ("ziprasidone mesylate trihydrate"), to pharmaceutical compositions containing ziprasidone mesylate trihydrate, and to methods of administering ziprasidone mesylate trihydrate to treat psychotic diseases.
Abstract: Corticotropin-releasing factor (CRF) antagonists having formulae (I), (II) or (III) wherein the dashed lines, A, B, Y, Z, G, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.16 and R.sub.17 are as defined in the description, and processes for preparing them. These compounds and their pharmaceutically acceptable salts are useful in the treatment of CNS and stress-related disorders.
Abstract: The present invention relates to novel compounds of the formula I, described above, and their pharmaceutically acceptable salts, and pharmaceutical compositions and methods of treating neurodegenerative and CNS-trauma related conditions.
Type:
Grant
Filed:
May 14, 1997
Date of Patent:
October 5, 1999
Assignee:
Pfizer Inc.
Inventors:
Bertrand L. Chenard, Willard M. Welch, Jr.